Anti-VEGF Aptamer Pegaptanib Reveals Two-Step Binding Mechanism to Block Angiogenesis

Vascular endothelial growth factor (VEGF) drives pathological angiogenesis in diseases including neovascular age-related macular degeneration (nAMD) and various cancers. Pegaptanib, one of the earliest approved anti-VEGF biologics, contains t44.27—a heavily 2′-modified 27-nucleotide RNA aptamer that binds VEGF165 with high affinity. Despite its clinical use, the molecular mechanism by which t44.27 selectively targets VEGF and antagonizes its function had remained poorly understood.

Using solution-state NMR spectroscopy as the primary tool, Takeuchi and colleagues systematically characterized the binding of t44.27 to the heparin-binding domain (HBD) of VEGF165. The HBD is the site through which VEGF interacts with heparan sulfate proteoglycans on cell surfaces and in the extracellular matrix—interactions critical for receptor presentation and angiogenic signaling. The aptamer is extensively 2′-modified (largely 2′-fluoro and 2′-O-methyl substitutions) for nuclease resistance, and binds VEGF HBD in a Ca2+-dependent manner.

The central finding is that t44.27 engages VEGF HBD through a two-step recognition process. In the first step, a structured region of the aptamer makes a transient, lower-affinity contact with VEGF HBD. In the second step, a more extensive interaction surface is recruited, forming a tight, stable complex. Ca2+ ions are shown to stabilize base-pairing within t44.27 that is necessary for productive initial docking. Without adequate Ca2+, the aptamer cannot adopt the conformation required for the first step, impairing overall binding. Crucially, it is the tight second-step complex—not the transient initial contact—that is responsible for competitive inhibition of heparin binding to VEGF HBD, explaining the aptamer's antagonistic activity.

These findings have meaningful implications for understanding therapeutic aptamers broadly. They demonstrate that functional inhibition can require a sequential binding process, where an initial encounter complex is necessary to template the formation of the high-affinity, functionally active complex. This parallels induced-fit and conformational-selection mechanisms well-documented in protein-protein and protein-small molecule interactions but less characterized for RNA aptamers against protein targets.

From a longevity and healthy aging perspective, VEGF-driven angiogenesis contributes not only to nAMD—a leading cause of vision loss in older adults—but also to tumor vascularization and potentially to vascular dysfunction in aging tissues. Better mechanistic understanding of how RNA aptamers inhibit VEGF could facilitate the design of improved aptamers with optimized binding kinetics, reduced calcium dependence, or enhanced tissue penetration, potentially benefiting aging-related conditions beyond the eye.